Akero Therapeutics Inc (NASDAQ: AKRO) on Tuesday, plunged -0.20% from the previous trading day, before settling in for the closing price of $54.03. Within the past 52 weeks, AKRO’s price has moved between $21.02 and $58.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -5.28% annually for the last half of the decade. The company achieved an average annual earnings per share of -1.23%. With a float of $71.74 million, this company’s outstanding shares have now reached $79.67 million.
In an organization with 63 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Akero Therapeutics Inc (AKRO) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Akero Therapeutics Inc is 10.01%, while institutional ownership is 101.98%. The most recent insider transaction that took place on Jun 18 ’25, was worth 363,041. In this transaction President and CEO of this company sold 6,620 shares at a rate of $54.84, taking the stock ownership to the 549,867 shares. Before that another transaction happened on Jun 18 ’25, when Company’s Chief Technology Officer sold 848 for $54.84, making the entire transaction worth $46,504. This insider now owns 23,452 shares in total.
Akero Therapeutics Inc (AKRO) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -1.23% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -10.29% during the next five years compared to -5.28% drop over the previous five years of trading.
Akero Therapeutics Inc (NASDAQ: AKRO) Trading Performance Indicators
Akero Therapeutics Inc (AKRO) is currently performing well based on its current performance indicators. A quick ratio of 16.80 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.75, a number that is poised to hit -0.90 in the next quarter and is forecasted to reach -4.36 in one year’s time.
Technical Analysis of Akero Therapeutics Inc (AKRO)
Let’s dig in a bit further. During the last 5-days, its volume was 1.94 million. That was better than the volume of 1.51 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 50.00%.
During the past 100 days, Akero Therapeutics Inc’s (AKRO) raw stochastic average was set at 85.14%, which indicates a significant increase from 44.64% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 25.69% in the past 14 days, which was lower than the 64.60% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $45.94, while its 200-day Moving Average is $37.84. However, in the short run, Akero Therapeutics Inc’s stock first resistance to watch stands at $54.80. Second resistance stands at $55.67. The third major resistance level sits at $56.38. If the price goes on to break the first support level at $53.21, it is likely to go to the next support level at $52.49. Assuming the price breaks the second support level, the third support level stands at $51.62.
Akero Therapeutics Inc (NASDAQ: AKRO) Key Stats
Market capitalization of the company is 4.30 billion based on 79,718K outstanding shares. Right now, sales total 0 K and income totals -252,060 K. The company made 0 K in profit during its latest quarter, and -70,730 K in sales during its previous quarter.
